Press Release titled Infomerics Upgrade Fredun Pharmaceuticals Credit Rating to BBB+, Boosts Financial Profile.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals received a credit rating upgrade from Infomerics Valuation and Rating Limited on its bank facilities of ₹156.17 crore, moving from IVR BBB to IVR BBB+ with a Stable outlook. The short-term rating was reaffirmed at IVR A2. This follows a similar upgrade from Brickwork earlier (from A3+ to A2). The upgrade covers ₹143.17 crore in long-term facilities and ₹13 crore in working capital facilities, and reflects stronger operational performance and disciplined capital management in FY24 and FY25. For FY25, the company reported total revenues of ₹456 crore, EBITDA of ₹55 crore, and profit after tax of ₹21 crore.
This is a positive development for shareholders — the upgrade signals improving credit quality, which may lower future borrowing costs and improve access to growth capital. It also strengthens institutional confidence as the company expands exports across Africa, Southeast Asia, CIS, and Latin America.